FDA Alert: FDA Restricts Use of Ocaliva (obeticholic acid) in Primary Biliary Cholangitis Patients with Advanced Cirrhosis Due to Risk of Serious Liver Injury

FDA Alert: FDA Restricts Use of Ocaliva (obeticholic acid) in Primary Biliary Cholangitis Patients with Advanced Cirrhosis Due to Risk of Serious Liver Injury

Comments

Popular posts from this blog

The conflict in Gaza: a view from Israel - The Lancet

George F. Will - Skip the lecture on Israel's 'risks for peace'